Key features and details
- Mouse monoclonal [BNI3] to CTLA4
- Suitable for: IP, ICC/IF, Flow Cyt, IHC-Fr
- Reacts with: Human
- Isotype: IgG2a
Product nameAnti-CTLA4 antibody [BNI3]
See all CTLA4 primary antibodies
DescriptionMouse monoclonal [BNI3] to CTLA4
SpecificityIHC-P has been removed following customer feedback of no signal in this application. If you are looking for a CTLA4 antibody for use in IHC-P we would recommend our rabbit monoclonal ab227709 specifically designed for use in this application.
Tested applicationsSuitable for: IP, ICC/IF, Flow Cyt, IHC-Frmore details
Species reactivityReacts with: Human
Human CTLA-4/human IgG heavy chain fusion protein (CTLA-4/Ig).
- ICC/FACS: B cells
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid repeated freeze / thaw cycles.
Storage bufferpH: 7.20
Preservative: 0.09% Sodium azide
Constituents: 0.87% Sodium chloride, 0.14% Monobasic dihydrogen sodium phosphate
Concentration information loading...
Our Abpromise guarantee covers the use of ab19792 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IP||Use at an assay dependent concentration.|
|ICC/IF||Use at an assay dependent concentration.|
|Flow Cyt||Use at an assay dependent concentration.
ab170191 - Mouse monoclonal IgG2a, is suitable for use as an isotype control with this antibody.
|IHC-Fr||Use at an assay dependent concentration.|
FunctionInhibitory receptor acting as a major negative regulator of T-cell responses. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory coreceptor CD28.
Tissue specificityWidely expressed with highest levels in lymphoid tissues. Detected in activated T-cells where expression levels are 30- to 50-fold less than CD28, the stimulatory coreceptor, on the cell surface following activation.
Involvement in diseaseGenetic variation in CTLA4 influences susceptibility to systemic lupus erythematosus (SLE) [MIM:152700]. SLE is a chronic, inflammatory and often febrile multisystemic disorder of connective tissue. It affects principally the skin, joints, kidneys and serosal membranes. SLE is thought to represent a failure of the regulatory mechanisms of the autoimmune system.
Note=Genetic variations in CTLA4 may influence susceptibility to Graves disease, an autoimmune disorder associated with overactivity of the thyroid gland and hyperthyroidism.
Genetic variation in CTLA4 is the cause of susceptibility to diabetes mellitus insulin-dependent type 12 (IDDM12) [MIM:601388]. A multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical fetaures are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.
Genetic variation in CTLA4 is the cause of susceptibility to celiac disease type 3 (CELIAC3) [MIM:609755]. It is a multifactorial disorder of the small intestine that is influenced by both environmental and genetic factors. It is characterized by malabsorption resulting from inflammatory injury to the mucosa of the small intestine after the ingestion of wheat gluten or related rye and barley proteins. In its classic form, celiac disease is characterized in children by malabsorption and failure to thrive.
Sequence similaritiesContains 1 Ig-like V-type (immunoglobulin-like) domain.
modificationsN-glycosylation is important for dimerization.
Phosphorylation at Tyr-201 prevents binding to the AP-2 adapter complex, blocks endocytosis, and leads to retention of CTLA4 on the cell surface.
Cellular localizationCell membrane. Exists primarily an intracellular antigen whose surface expression is tightly regulated by restricted trafficking to the cell surface and rapid internalisation and.
- Information by UniProt
- ALPS5 antibody
- CD 152 antibody
- CD antibody
ab19792 has been referenced in 5 publications.
- Kümpers C et al. Immune Cell Infiltration of the Primary Tumor, Not PD-L1 Status, Is Associated With Improved Response to Checkpoint Inhibition in Metastatic Melanoma. Front Med (Lausanne) 6:27 (2019). PubMed: 30931305
- Gulati N et al. Psoriasis is characterized by deficient negative immune regulation compared to transient delayed-type hypersensitivity reactions. F1000Res 4:149 (2015). PubMed: 26236467
- Mittal AK et al. Role of CTLA4 in the proliferation and survival of chronic lymphocytic leukemia. PLoS One 8:e70352 (2013). WB ; Human . PubMed: 23936412
- Suárez-Fariñas M et al. Expanding the Psoriasis Disease Profile: Interrogation of the Skin and Serum of Patients with Moderate-to-Severe Psoriasis. J Invest Dermatol : (2012). IHC-Fr ; Human . PubMed: 22763790
- Kozik P et al. A screen for endocytic motifs. Traffic 11:843-55 (2010). PubMed: 20214754